Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P.

Blood. 2018 Jul 17. pii: blood-2018-02-833582. doi: 10.1182/blood-2018-02-833582. [Epub ahead of print]

PMID:
30018080
2.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Blatt K, Menzl I, Eisenwort G, Cerny-Reiterer S, Herrmann H, Herndlhofer S, Stefanzl G, Sadovnik I, Berger D, Keller A, Hauswirth A, Hoermann G, Willmann M, Rülicke T, Sill H, Sperr WR, Mannhalter C, Melo JV, Jäger U, Sexl V, Valent P.

Neoplasia. 2018 Jun;20(6):632-642. doi: 10.1016/j.neo.2018.04.004. Epub 2018 May 15.

3.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P.

Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8.

4.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

5.

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.

Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, Hadzijusufovic E, Berger D, Herrmann H, Hoermann G, Valent P, Rülicke T.

Exp Hematol. 2018 Jan;57:50-59.e6. doi: 10.1016/j.exphem.2017.09.012. Epub 2017 Oct 12.

PMID:
29031704
6.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Stefanzl G, Berger D, Cerny-Reiterer S, Blatt K, Eisenwort G, Sperr WR, Hoermann G, Lind K, Hauswirth AW, Bettelheim P, Sill H, Melo JV, Jäger U, Valent P.

Oncotarget. 2017 Jun 28;8(40):67709-67722. doi: 10.18632/oncotarget.18810. eCollection 2017 Sep 15.

7.

BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils.

Smiljkovic D, Blatt K, Stefanzl G, Dorofeeva Y, Skrabs C, Focke-Tejkl M, Sperr WR, Jaeger U, Valenta R, Valent P.

Allergy. 2017 Nov;72(11):1666-1676. doi: 10.1111/all.13166. Epub 2017 Apr 20.

8.

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma.

Blatt K, Herrmann H, Stefanzl G, Sperr WR, Valent P.

Oncotarget. 2016 Oct 4;7(40):65627-65642. doi: 10.18632/oncotarget.11593.

9.

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.

Cuapio A, Post M, Cerny-Reiterer S, Gleixner KV, Stefanzl G, Basilio J, Herndlhofer S, Sperr WR, Brons NH, Casanova E, Zimmer J, Valent P, Hofer E.

Oncotarget. 2016 Jul 19;7(29):46466-46481. doi: 10.18632/oncotarget.10191.

10.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Sadovnik I, Hoelbl-Kovacic A, Herrmann H, Eisenwort G, Cerny-Reiterer S, Warsch W, Hoermann G, Greiner G, Blatt K, Peter B, Stefanzl G, Berger D, Bilban M, Herndlhofer S, Sill H, Sperr WR, Streubel B, Mannhalter C, Holyoake TL, Sexl V, Valent P.

Clin Cancer Res. 2016 Apr 15;22(8):2051-61. doi: 10.1158/1078-0432.CCR-15-0767. Epub 2015 Nov 25.

11.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülicke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P.

Blood. 2015 Dec 24;126(26):2832-41. doi: 10.1182/blood-2015-03-637728. Epub 2015 Oct 20. Erratum in: Blood. 2018 Mar 22;131(12 ):1390.

12.

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.

Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9.

13.

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.

Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P.

Oncotarget. 2015 Feb 20;6(5):3071-84.

14.

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.

Herrmann H, Sadovnik I, Cerny-Reiterer S, Rülicke T, Stefanzl G, Willmann M, Hoermann G, Bilban M, Blatt K, Herndlhofer S, Mayerhofer M, Streubel B, Sperr WR, Holyoake TL, Mannhalter C, Valent P.

Blood. 2014 Jun 19;123(25):3951-62. doi: 10.1182/blood-2013-10-536078. Epub 2014 Apr 28.

15.

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.

Cerny-Reiterer S, Meyer RA, Herrmann H, Peter B, Gleixner KV, Stefanzl G, Hadzijusufovic E, Pickl WF, Sperr WR, Melo JV, Maeda H, Jäger U, Valent P.

Oncotarget. 2014 Mar 15;5(5):1198-211.

16.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Sadovnik I, Lierman E, Peter B, Herrmann H, Suppan V, Stefanzl G, Haas O, Lion T, Pickl W, Cools J, Vandenberghe P, Valent P.

Exp Hematol. 2014 Apr;42(4):282-293.e4. doi: 10.1016/j.exphem.2013.12.007. Epub 2014 Jan 6.

17.

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.

Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P.

J Leukoc Biol. 2014 Jan;95(1):95-104. doi: 10.1189/jlb.1112609. Epub 2013 Sep 19.

PMID:
24052572
18.

Expression of sulfotransferases and sulfatases in human breast cancer: impact on resveratrol metabolism.

Miksits M, Wlcek K, Svoboda M, Thalhammer T, Ellinger I, Stefanzl G, Falany CN, Szekeres T, Jaeger W.

Cancer Lett. 2010 Mar 28;289(2):237-45. doi: 10.1016/j.canlet.2009.08.020. Epub 2009 Sep 10.

PMID:
19747768

Supplemental Content

Loading ...
Support Center